Assessment of the safety and efficacy of fondaparinux as an anticoagulant in haemofiltraion in patients with acute renal failure

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000401651

Enrollment

Registered

2005-09-14

Start date

2004-06-04

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The active group will be given ondaparinux for anticoagulation for the first filter only during their course of haemofiltration. The decision to commence or cease haemofiltraion will remain with treating physician.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

The study will be conducted in the Intensive Care Unit at The Royal Melbourne Hospital and will aim to include patients who fulfill the following criteria: 1.Adult patients admitted to the ICU with an expected stay of more than 48h. 2.Patients who require continuous renal replacement therapy. 3.Patients who consent or if the patient is incompetent, the next-of-kin who consent, to inclusion in the study.

Exclusion criteria

1.Patients who are pregnant. 2.Patients with a contra-indication to anticoagulation for pre-existing bleeding diathesis. 3.Patients or next-to-kin who do not consent to study inclusion.

Outcome results